Nicotinonitrile as an essential scaffold in medicinal chemistry: an updated review (2015– present)

Many studies have been carried out to find synthetic pathways to nicotinonitriles (3-cyanopyridines) and their analogs, which has resulted in a substantial amount of knowledge on their biological, therapeutic, and medical characteristics. Some of nicotinonitrile derivatives have emerged as marketed drugs such as bosutinib, milrinone, neratinib

[1]  M. Ismail,et al.  Synthesis, In Silico Study and Antibacterial Evaluation of New Cyanopyridine Based Scaffold , 2021, Polycyclic Aromatic Compounds.

[2]  M. Mohamed,et al.  Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors. , 2021, Bioorganic chemistry.

[3]  A. Tewari,et al.  Study of the structure-bioactivity of fleximers: synthesis, crystal structure, Hirshfeld surface analysis, and anti-inflammatory assays , 2021 .

[4]  Mohamed S. Nafie,et al.  Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches. , 2021, Bioorganic chemistry.

[5]  E. Santali,et al.  Discovery of pyridine- sulfonamide hybrids as a new scaffold for the development of potential VEGFR-2 inhibitors and apoptosis inducers. , 2021, Bioorganic chemistry.

[6]  M. El-Zoghbi,et al.  3-Cyano-2-oxa-pyridines: a promising template for diverse pharmacological activities , 2021 .

[7]  M. Ismail,et al.  New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study. , 2020, Bioorganic chemistry.

[8]  G. Abuo-Rahma,et al.  Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. , 2020, European journal of medicinal chemistry.

[9]  Ahmed E. M. Mekky,et al.  Synthesis and in vitro study of new coumarin derivatives linked to nicotinonitrile moieties as potential acetylcholinesterase inhibitors , 2020 .

[10]  Ahmed E. M. Mekky,et al.  Novel Nicotinonitriles and Thieno[2,3‐ b ]pyridines as Potent Biofilm and COX‐2 Inhibitors: Synthesis, In Vitro and In Silico Studies , 2020 .

[11]  Ahmed E. M. Mekky,et al.  Novel nicotinonitrile-coumarin hybrids as potential acetylcholinesterase inhibitors: design, synthesis, in vitro and in silico studies , 2020, Journal of the Iranian Chemical Society.

[12]  Ahmed E. M. Mekky,et al.  Synthesis, in-vitro antibacterial and anticancer screening of novel nicotinonitrile-coumarin hybrids utilizing piperazine citrate , 2020 .

[13]  Farag F. Sherbiny,et al.  Antimicrobial screening and pharmacokinetic profiling of novel phenyl-[1,2,4]triazolo[4,3-a]quinoxaline analogues targeting DHFR and E. coli DNA gyrase B. , 2020, Bioorganic chemistry.

[14]  M. Ismail,et al.  Apoptosis: A target for anticancer therapy with novel cyanopyridines. , 2019, Bioorganic chemistry.

[15]  Jianping Lin,et al.  Identification of new potent A1 adenosine receptor antagonists using a multistage virtual screening approach. , 2019, European journal of medicinal chemistry.

[16]  Y. Mabkhot,et al.  Facile synthesis and antiproliferative activity of new 3-cyanopyridines , 2019, BMC Chemistry.

[17]  Marwa M. Abu‐Serie,et al.  Dual VEGFR-2/PIM-1 kinase inhibition towards surmounting the resistance to antiangiogenic agents via hybrid pyridine and thienopyridine-based scaffolds: Design, synthesis and biological evaluation. , 2019, Bioorganic chemistry.

[18]  M. Gouda,et al.  Synthesis and Antioxidant Activity of Some Novel Nicotinonitrile Derivatives Bearing a Furan Moiety , 2019, Journal of Heterocyclic Chemistry.

[19]  A. Moustafa,et al.  Design, synthesis, and antimicrobial activity of fluorophore 1,2,3-triazoles linked nicotinonitrile derivatives , 2019, Synthetic Communications.

[20]  S. S. Shaban,et al.  Synthesis and biological assessment of novel cyanopyridine derivatives , 2019, Synthetic Communications.

[21]  Hamed I. Ali,et al.  Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds. , 2019, Bioorganic & medicinal chemistry.

[22]  W. Hamama,et al.  Highlights on the synthesis of novel phenothiazine‐based azines scaffold as antioxidant agents , 2019 .

[23]  Ahmed B. M. Mehany,et al.  Design, synthesis, cytotoxicity screening and molecular docking of new 3-cyanopyridines as survivin inhibitors and apoptosis inducers. , 2019, Bioorganic chemistry.

[24]  M. Al-Shorbagy,et al.  Design, Synthesis and Screening of 4,6-Diaryl Pyridine and Pyrimidine Derivatives as Potential Cytotoxic Molecules. , 2018, Chemical & pharmaceutical bulletin.

[25]  Duane D. Miller,et al.  Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors. , 2018, European journal of medicinal chemistry.

[26]  Yifan Feng,et al.  Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. , 2018, Bioorganic & medicinal chemistry.

[27]  K. Bhalla,et al.  HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia , 2017, Leukemia.

[28]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[29]  Bahgat R. M. Hussein,et al.  Synthesis, in vitro Antibacterial and in vivo Anti-Inflammatory Activity of Some New Pyridines , 2017, Pharmaceutical Chemistry Journal.

[30]  ElSayed M Shalaby,et al.  Synthesis, molecular modeling studies and bronchodilation properties of nicotinonitrile containing-compounds. , 2017, European journal of medicinal chemistry.

[31]  Yuan Sun,et al.  Designing multi-targeted agents: An emerging anticancer drug discovery paradigm. , 2017, European journal of medicinal chemistry.

[32]  X. Zhai,et al.  Synthesis, biological evaluation and molecular modeling of imidazo[1,2-a]pyridine derivatives as potent antitubulin agents. , 2017, Bioorganic & medicinal chemistry.

[33]  K. Abouzid,et al.  Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities. , 2017, European journal of medicinal chemistry.

[34]  M. Abdel-Latif,et al.  Design, synthesis and biological screening of some novel celecoxib and etoricoxib analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. , 2017, Bioorganic chemistry.

[35]  Huda R. M. Rashdan,et al.  A Novel Approach of Potent Antioxidant and Antimicrobial Agents Containing Coumarin Moiety Accompanied with Cytotoxicity Studies on the Newly Synthesized Derivatives , 2017 .

[36]  M. Morioka.  3-Cyano-6-(5-methyl-3-pyrazoloamino) pyridines (Part 2): A dual inhibitor of Aurora kinase and tubulin polymerization. , 2016, Bioorganic & medicinal chemistry letters.

[37]  ElSayed M Shalaby,et al.  Crystal Structure Studies and Bronchodilation Properties of Novel Benzocycloheptapyridines , 2016, Journal of Chemical Crystallography.

[38]  M. Gouda,et al.  Synthesis and Antioxidant Evaluation of Some Nicotinonitriles , 2016 .

[39]  Praveen P. Singh,et al.  Polymorphic study and anti-inflammatory activity of a 3-cyano-2-pyridone based flexible model , 2016 .

[40]  S. Sabatini,et al.  p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening , 2015, Molecules.

[41]  Jian Ding,et al.  Targeting PI3Kδ: Emerging Therapy for Chronic Lymphocytic Leukemia and Beyond , 2015, Medicinal research reviews.

[42]  Yusuke Nakamura,et al.  A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity. , 2015, Bioorganic & medicinal chemistry.

[43]  M. Elaasser,et al.  Synthesis and biological evaluation of new pyridines containing imidazole moiety as antimicrobial and anticancer agents , 2015 .

[44]  Wei Li,et al.  Recent Advances on Small-Molecule Survivin Inhibitors , 2015, Current medicinal chemistry.

[45]  Shudong Wang,et al.  Targeting Pim kinases for cancer treatment: opportunities and challenges. , 2015, Future medicinal chemistry.

[46]  Aladdin M. Srour,et al.  Synthesis, bioassay, and QSAR study of bronchodilatory active 4H-pyrano[3,2-c]pyridine-3-carbonitriles. , 2015, European journal of medicinal chemistry.

[47]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[48]  V. Shah,et al.  Synthesis, Characterization and antimicrobial activity of Cyanopyridine derivatives with Vanillin. , 2014 .

[49]  A. Chakravarti,et al.  Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle. , 2013, Bioorganic & medicinal chemistry letters.

[50]  S. Koul,et al.  Role of p38 MAP Kinase Signal Transduction in Solid Tumors. , 2013, Genes & cancer.

[51]  Chun-Peng Liao,et al.  Loss of Survivin in the Prostate Epithelium Impedes Carcinogenesis in a Mouse Model of Prostate Adenocarcinoma , 2013, PloS one.

[52]  A. Kraft,et al.  Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice , 2013, Journal of Hematology & Oncology.

[53]  M. Davids,et al.  Targeting the B cell receptor pathway in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.

[54]  C. Rommel,et al.  PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. , 2011, Cancer discovery.

[55]  P. Sunnerhagen,et al.  Design, synthesis, and biological evaluation of chromone-based p38 MAP kinase inhibitors. , 2011, Journal of medicinal chemistry.

[56]  E. Gabrielson,et al.  High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells , 2011, Proceedings of the National Academy of Sciences.

[57]  A. Mor,et al.  Experimental Conditions That Enhance Potency of an Antibacterial Oligo-Acyl-Lysyl , 2010, Antimicrobial Agents and Chemotherapy.

[58]  Yanying Zhao,et al.  Survivin gene silencing sensitizes prostate cancer cells to selenium growth inhibition , 2010, BMC Cancer.

[59]  J. Li,et al.  Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines. , 2009, Experimental hematology.

[60]  A. Abadi,et al.  Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors. , 2009, Bioorganic & medicinal chemistry.

[61]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[62]  H. Hsieh,et al.  Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers , 2009, Molecular Cancer.

[63]  J. Pollard,et al.  Discovery and development of aurora kinase inhibitors as anticancer agents. , 2009, Journal of medicinal chemistry.

[64]  S. Hilsenbeck,et al.  Inhibition of the p 38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells , 2009 .

[65]  J. Yim,et al.  Antibacterial potential of Antarctic lichens against human pathogenic Gram‐positive bacteria , 2008, Phytotherapy research : PTR.

[66]  Qing Jiang,et al.  Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.

[67]  K. Jacobson,et al.  Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.

[68]  Rou-shayn Chen,et al.  DYT1 mutation in a cohort of Taiwanese primary dystonias. , 2006, Parkinsonism & related disorders.

[69]  M. Lenassi,et al.  The role of p 38 MAP kinase in cancer cell apoptosis , 2006 .

[70]  M. Shibuya,et al.  The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. , 2005, Clinical science.

[71]  C. Supuran,et al.  Protein tyrosine kinase inhibitors as anticancer agents , 2004 .

[72]  E. Giacobini.  Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease , 2003, Neurochemical Research.

[73]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[74]  M. Winey,et al.  Human Mps1 protein kinase is required for centrosome duplication and normal mitotic progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Yusuke Nakamura,et al.  Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs , 2003, Oncogene.

[76]  Lionel Arnaud,et al.  Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication , 2002, The EMBO journal.

[77]  Yusuke Nakamura,et al.  Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. , 2002, DNA research : an international journal for rapid publication of reports on genes and genomes.

[78]  J. Labbé,et al.  Mps1 Is a Kinetochore-Associated Kinase Essential for the Vertebrate Mitotic Checkpoint , 2001, Cell.

[79]  J. Sebolt-Leopold.  Development of anticancer drugs targeting the MAP kinase pathway , 2000, Oncogene.

[80]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[81]  H. Enslen,et al.  Molecular determinants that mediate selective activation of p38 MAP kinase isoforms , 2000, The EMBO journal.

[82]  B. Spencer‐Dene,et al.  An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. , 2000, Development.

[83]  A. Ullrich,et al.  Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.

[84]  T. Palmer,et al.  Adenosine receptors , 1995, Neuropharmacology.

[85]  D. Glover,et al.  Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles , 1995, Cell.

[86]  Eric L. Weiss,et al.  Yeast spindle pole body duplication gene MPS1 encodes an essential dual specificity protein kinase. , 1995, The EMBO journal.

[87]  P. Laird,et al.  Pim-1 levels determine the size of early B lymphoid compartments in bone marrow , 1993, The Journal of experimental medicine.

[88]  G. Mills,et al.  Expression of TTK, a novel human protein kinase, is associated with cell proliferation. , 1992, The Journal of biological chemistry.

[89]  M. Kirschner,et al.  Synergistic induction of mesoderm by FGF and TGF-β and the identification of an mRNA coding for FGF in the early xenopus embryo , 1987, Cell.

[90]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.